Chinese Biopharmaceutical Firm KeChow Pharma Closes on $45M Series C Funding Round

According to yigoonet.com, KeChow Pharma, Inc. ("KeChow Pharma"), a Chinese biopharmaceutical company focused on novel drug discovery, has completed $45 million Series C round of financing, led by Decheng Capital, with participation from Qiming Venture Partners, Sherpa Capital, and existing investor Grains Valley Venture Capital. BFC Group acted as the exclusive financial advisor in this financing. The company has raised a total of $60M through four rounds of financing including the latest.

Proceeds of this round will be used to promote the clinical research and market application of a new anti-cancerous drug HL-085 developed by KeChow Pharma and enrich the company's product pipeline.

KeChow Pharma was founded by Dr. Tian Hongqi, Lilly Asia Ventures and Morningside Venture Capital in 2014. The company operates facilities in Shanghai Zhangjiang High-Tech Park and is recognized as a key biotech company by the local government. 

KeChow Pharma's strategy is to discover targeted small molecule drugs that have competitive advantages over existing therapies and co-develop drugs with partners. The company focuses on the research and development of new anti-cancerous drugs, with the purpose of providing high-quality drugs to meet clinical needs.

Dr. Tian Hongqi, founder and chairman of KeChow Pharma, said, "As an innovation-driven company, our goal is to develop best-in-class innovative drugs to meet clinical needs, meanwhile cultivating outstanding talents, so as to strengthen our team building and develop the company into a strong new drug development company."

Founded in 2012 and Located in Shanghai and Silicon Valley, Decheng Capital is a leading investment firm that provides capital and strategic support to early-stage life science companies and growth-stage healthcare companies. The company has over $1 billion in capital under management.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.